Ray Gerald L & Associates Ltd. reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.4% during the first quarter, Holdings Channel reports. The institutional investor owned 122,519 shares of the medical research company’s stock after selling 530 shares during the period. Amgen accounts for approximately 2.8% of Ray Gerald L & Associates Ltd.’s holdings, making the stock its 5th largest position. Ray Gerald L & Associates Ltd.’s holdings in Amgen were worth $20,102,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares during the last quarter. Norges Bank acquired a new position in Amgen during the fourth quarter valued at approximately $1,016,913,000. Loomis Sayles & Co. L P raised its position in Amgen by 4.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 3,001,021 shares of the medical research company’s stock valued at $438,779,000 after buying an additional 133,918 shares during the last quarter. Bank of Montreal Can raised its position in Amgen by 10.5% in the first quarter. Bank of Montreal Can now owns 2,837,456 shares of the medical research company’s stock valued at $465,543,000 after buying an additional 269,586 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Amgen during the fourth quarter valued at approximately $275,209,000. Institutional investors and hedge funds own 78.87% of the company’s stock.
Amgen Inc. (NASDAQ AMGN) opened at 181.06 on Tuesday. The company has a 50-day moving average price of $170.78 and a 200-day moving average price of $165.90. The stock has a market cap of $133.15 billion, a P/E ratio of 17.20 and a beta of 1.35. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.15. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.90 earnings per share. On average, analysts anticipate that Amgen Inc. will post $12.47 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://stocknewstimes.com/2017/07/25/amgen-inc-amgn-shares-sold-by-ray-gerald-l-associates-ltd.html.
AMGN has been the subject of several analyst reports. Deutsche Bank AG initiated coverage on Amgen in a research note on Friday, June 23rd. They issued a “hold” rating and a $172.00 target price for the company. Credit Suisse Group reiterated a “hold” rating and issued a $178.00 target price on shares of Amgen in a research note on Tuesday, April 4th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 target price for the company in a research note on Monday, March 27th. ValuEngine lowered Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Oppenheimer Holdings, Inc. set a $189.00 target price on Amgen and gave the company a “buy” rating in a research note on Monday, June 5th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have issued a buy rating and three have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $185.21.
In other news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
